CLSD 250117 1.50P (CLSD250117P1500) Stock Options, News & Quotes

0.70
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Jan 22 06:06

update

$Clearside Biomedical (CLSD.US)$ Reuters· just
Clearside Biomedical Announces Its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Jaguar8

Jan 22 06:05

NEWS

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Wednesday, 22nd January at 7:05 am
- ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy -
- Continued Global Expansion of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® -
ALPHARETTA, Ga.,...

Stock_Drift

Dec 19, 2024 06:12

$Clearside Biomedical (CLSD.US)$

Jaguar8

Dec 19, 2024 06:06

NEWS

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Thursday, 19th December at 7:05 am
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the official journal of The Royal Colleg...

Jaguar8

Nov 25, 2024 06:09

NEWS

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Clearside Biomedical (NASDAQ: CLSD) showcased its suprachoroidal delivery technology and pipeline programs at multiple medical meetings across Asia, Europe, and the United States. The company made a significant impact at the 17th Asia-Pacific Vitreo-Retina Society Congress in Singapore with presentations on ODYSSEY topline resul...